Enanta Pharmaceuticals Inc (ENTA) stock saw a decline, ending the day at $5.75 which represents a decrease of $-0.10 or -1.71% from the prior close of $5.85. The stock opened at $6 and touched a low ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective reduced by HC Wainwright from $27.00 to $18.00 in ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology ...

H.C. Wainwright analyst Ed Arce has maintained their bullish stance on ENTA stock, giving a Buy rating on December 13.Don't Miss Our Christmas ...

Enanta Pharmaceuticals (NETA) stock fell as the company plans to appeal a court ruling favoring Pfizer in a patent dispute over COVID-19 pill Paxlovid. Read more here.

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...